Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

McMaster University

$90,000.00

Discovery and Characterization of Novel Combination Antifungal Therapeutics

EF 2013-14

Résumé
Invasive fungal infections are a leading cause of human mortality worldwide that kill at least as many people as other infectious diseases such as tuberculosis or malaria. Despite the enormous clinical impact, fungal infections remain understudied and underdiagnosed as compared to other infectious diseases. The treatment of invasive fungal infections is notoriously difficult. There are a limited number of available drugs with selective toxicity to fungi, which share close evolutionary relationships with their human hosts. The fact that the emergence of antifungal drug resistance dramatically outpaces the development of new antifungal treatments emphasizes the importance of identifying and characterizing novel therapeutics. The challenge for researchers is to identify novel drugs with antifungal activity, uncover new fungal specific targets to minimize human toxicity, and to develop therapeutic strategies that will limit the development of drug resistance. We believe using combination therapies to treat fungal infections can overcome these three obstacles. Combination therapies are currently used to treat a variety of diseases including infections caused by HIV and cancer. This proposal aims to discover and characterize off-patent bioactive compounds that increase the effectiveness of current antifungal regimens against a variety of fungal species. Using high-throughput methods I have screened ~143,000 different drug combinations against diverse fungal species. Those combinations that increase the efficacy of antifungal drugs against numerous fungal pathogens will be further analyzed to decipher mechanism of action using chemical genomic and biochemical approaches. Finally, the clinical relevance of the candidate combination therapy will be evaluated using animal models of fungal infection. This research has the capacity to uncover much-needed novel therapeutic options for the treatment of fungal disease.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
300377
Name
Robbins Nicole
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Discovery and Characterization of Novel Combination Antifungal Therapeutics
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antifungal; Aspergillus Fumigatus; Candida Albicans; Chemical Genomics; Cryptococcus Neoformans; Drug Target; Infectious Disease; Microbiology; Resistance; Stress Response
Abstract
Invasive fungal infections are a leading cause of human mortality worldwide that kill at least as many people as other infectious diseases such as tuberculosis or malaria. Despite the enormous clinical impact, fungal infections remain understudied and underdiagnosed as compared to other infectious diseases. The treatment of invasive fungal infections is notoriously difficult. There are a limited number of available drugs with selective toxicity to fungi, which share close evolutionary relationships with their human hosts. The fact that the emergence of antifungal drug resistance dramatically outpaces the development of new antifungal treatments emphasizes the importance of identifying and characterizing novel therapeutics. The challenge for researchers is to identify novel drugs with antifungal activity, uncover new fungal specific targets to minimize human toxicity, and to develop therapeutic strategies that will limit the development of drug resistance. We believe using combination therapies to treat fungal infections can overcome these three obstacles. Combination therapies are currently used to treat a variety of diseases including infections caused by HIV and cancer. This proposal aims to discover and characterize off-patent bioactive compounds that increase the effectiveness of current antifungal regimens against a variety of fungal species. Using high-throughput methods I have screened ~143,000 different drug combinations against diverse fungal species. Those combinations that increase the efficacy of antifungal drugs against numerous fungal pathogens will be further analyzed to decipher mechanism of action using chemical genomic and biochemical approaches. Finally, the clinical relevance of the candidate combination therapy will be evaluated using animal models of fungal infection. This research has the capacity to uncover much-needed novel therapeutic options for the treatment of fungal disease.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Robbins, Nicole
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~